How to Help Your Patients Save Money on MetroGel: A Provider's Guide to Savings Programs

Cost is one of the most common reasons patients don't fill or refill their MetroGel (metronidazole topical gel) prescriptions. When a 60g tube of brand-name MetroGel retails for $186–$482 at cash price, and insurance coverage varies widely, it's no surprise that some patients simply walk away from the pharmacy counter empty-handed.

As the prescriber, you have meaningful influence over the financial burden your patients face for this medication. This guide outlines the strategies and resources you can use to help patients afford MetroGel in 2026.

Understanding the MetroGel Cost Landscape

Providers should be aware of the wide pricing variation patients encounter:

Brand MetroGel 1% (60g): $186–$482 at retail cash price. Not covered by Medicare Part D. May be rejected or high-tiered on commercial plans.

Generic metronidazole 1% gel (60g): $78–$186 at retail cash price; $22–$34 with GoodRx or SingleCare coupon.

Generic metronidazole 0.75% gel (45g): $30–$43 at retail; as low as $5.24 with GoodRx for some formulations.

With insurance (generic, Tier 1–2): $0–$30 copay on most commercial plans and Medicare Part D.

Strategy 1: Prescribe Generic — It's the Most Effective Cost Lever

The most impactful decision you can make is to write the prescription for generic metronidazole topical gel rather than brand-name MetroGel. FDA-approved generics contain the same active ingredient at the same concentration and are bioequivalent. The cost difference can be 80–90% less.

If your prescription simply says "MetroGel" without "Dispense as Written (DAW)," pharmacists can typically substitute the generic. But explicitly writing for the generic and leaving off the brand name eliminates any ambiguity and avoids situations where a DAW code is applied in error.

Strategy 2: Verify Insurance Coverage at Prescribing

Coverage for metronidazole topical gel varies by plan. Most commercial plans cover the generic at Tier 1 or Tier 2. Medicare Part D covers the generic on most formularies but typically does not cover brand-name MetroGel.

Using your EHR's formulary checking tool or Surescripts integration can flag coverage issues before you send the prescription electronically. For patients on Medicare, confirming generic coverage before prescribing can prevent the patient from a surprise at the pharmacy.

Strategy 3: Educate Patients About GoodRx and SingleCare

Many patients don't know that third-party discount programs like GoodRx and SingleCare can dramatically reduce the out-of-pocket cost of generic metronidazole gel — even at pharmacies that accept their insurance. Key facts to share with patients:

GoodRx can bring the cost of generic metronidazole gel down to as low as $5.24–$22.18, depending on the strength and quantity.

SingleCare can bring the cost of a 60g tube of generic 1% gel to approximately $33.71.

Patients can present the coupon (on their phone) at checkout, even without registering or signing up.

Patients should compare the GoodRx/SingleCare price against their insurance copay at the same pharmacy — and use whichever is lower.

Strategy 4: Consider a 90-Day Supply for Long-Term Patients

Rosacea is chronic, and many patients use MetroGel for months or years. For patients on stable rosacea maintenance therapy, writing a 90-day supply prescription with refills can:

Reduce per-unit cost when filling through mail-order pharmacy (often 10–25% savings compared to monthly retail fills).

Reduce the number of trips to the pharmacy, improving adherence.

Simplify the prescription process for both patient and provider.

Strategy 5: Medicare Extra Help and Low-Income Subsidy

For patients on Medicare with limited income, the Extra Help (Low-Income Subsidy, or LIS) program can significantly reduce out-of-pocket drug costs. Under the Extra Help program, copays for covered medications — including generic metronidazole topical — can be reduced to a few dollars per fill. Patients can apply through the Social Security Administration at ssa.gov or by calling 1-800-772-1213.

Additionally, starting January 1, 2025, Medicare Part D includes a $2,000 annual out-of-pocket cap for covered drugs. Once patients hit this cap, their plan covers 100% of covered medication costs for the rest of the year.

Strategy 6: Manufacturer Programs and NeedyMeds

As of 2026, there is no publicly available manufacturer savings card or patient assistance program (PAP) specifically for brand-name MetroGel from Galderma. However, patients who need the brand and cannot afford it may find resources through:

NeedyMeds.org — a nonprofit database of PAPs, disease-based assistance programs, and discount drug cards.

RxAssist.org — a directory of manufacturer patient assistance programs.

Contacting Galderma directly to ask about access support for their dermatology product portfolio.

When Cost Is the Barrier: Consider a Therapeutic Alternative

If a patient consistently struggles to afford MetroGel or its generic, consider whether a lower-cost therapeutic alternative is appropriate. Generic azelaic acid (15% gel or 20% cream) is FDA-approved for rosacea, is widely available, and may be similarly affordable. Generic oral doxycycline at sub-antimicrobial doses is one of the most affordable evidence-based options for moderate-to-severe rosacea.

For help navigating pharmacy access challenges with your patients, visit medfinder for providers. Also see our guide on how to help your patients find MetroGel in stock for complementary pharmacy navigation strategies.